<DOC>
	<DOC>NCT01358344</DOC>
	<brief_summary>The purpose of this study is determine if SCH 530348 2.5 mg tablets containing a high percentage of drug as the free base are equivalent to tablets with the standard percentage when given to participants.</brief_summary>
	<brief_title>A Bioequivalence Study of SCH 530348 2.5 mg Tablets (P06558)</brief_title>
	<detailed_description />
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<mesh_term>Vorapaxar</mesh_term>
	<criteria>Inclusion criteria: Body Mass Index (BMI) between 18 and 32, inclusive Clinical laboratory tests within normal limits Free of any clinically significant disease that would interfere with the study evaluations Screening 12lead electrocardiogram (ECG) conduction intervals within genderspecific normal range Vital sign measurements within the following ranges: oral body temperature, 35.0°C to 37.5°C; systolic blood pressure, 90 to 140 mmHg; diastolic blood pressure, 45 to 90 mmHg; pulse rate, 40 to 100 beats per minute Female participants must be postmenopausal, surgically sterile, abstinent, or using medically accepted method of contraception for 3 months prior to the screening period, during the trial, and for 2 months after stopping the trial. Nonvasectomized men must agree to use acceptable contraception or to abstain from sexual intercourse during the trial and for 3 months after stopping the medication Female participants who are pregnant, intend to become pregnant (within 3 months of ending the study), or are breastfeeding History of coagulation disorder(s), thrombocytopenia, bleeding tendency, ulcers, or gastrointestinal bleeding History of cardiac abnormalities including clinically relevant ECGs, frequent palpitations or syncopal episodes Any surgical or medical condition that might significantly alter the absorption, distribution, metabolism or excretion of any drug History of any infectious disease within 4 weeks prior to drug administration Positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus (HIV) Positive screen for drugs with a high potential for abuse History of alcohol or drug abuse in the past 2 years Blood donation in the past 60 days Previous treatment with SCH 530348 Currently participating in another clinical study or has participated in a clinical study within 30 days Demonstrated allergic reactions Smokes more than 10 cigarettes or equivalent tobacco use per day History of malignancy Has received any protocoldefined treatment which could interfere with ability to participate in the trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>